Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report

All NewsJuly 1, 2025

Novo Nordisk executives overlooked warnings ahead of Wegovy’s launch, leading to supply issues, high costs, and challenges competing with Eli Lilly’s Zepbound.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent